Oncology Research Editorial Office

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.077270 - 30 December 2025

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.077269 - 30 December 2025

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.077268 - 30 December 2025

Abstract This article has no abstract. More >

Keiko Yanagihara^1,*, Masato Yoshida², Kensaku Awaji², Tamami Yamakawa¹, Sena Kato¹, Miki Tamura¹, Koji Nagata³

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.073891 - 30 December 2025

Abstract Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have transformed the management of hormone receptor–positive/HER2–negative (HR+/HER2–) advanced breast cancer, yet evidence for elderly or poor-performance patients remains limited. This study examined real-world outcomes of palbociclib plus endocrine therapy in Asian patients, with additional subgroup analyses by age and performance status. Methods: We retrospectively analyzed 46 consecutive Asian patients with recurrent or de novo HR+/HER2− breast cancer treated with first-line palbociclib plus ET between April 2021 and March 2025. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rate (ORR), disease control rate (DCR), and safety.… More >

Cheng-Hsun Chuang^1,2,3,#, Ping-Kun Tsai^3,4,5,6,#, Shih-Wen Kao^7,8, Yu-Hsun Wang^8,9,*, Chao-Bin Yeh^1,2,3,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.072875 - 30 December 2025

Abstract Background: To determine whether initiating a glucagon-like peptide-1 receptor agonist (GLP-1 RA) within 3 months of type 2 diabetes (T2DM) diagnosis alters the subsequent risk of overall and site-specific cancer and whether this association differs by baseline body-mass index (BMI). Methods: This retrospective cohort study used electronic health records from the TriNetX U.S. research network. Adults aged 20 years or older diagnosed with T2DM between 2016 and 2024 were included if they received any hypoglycemic agents within 3 months before and after diagnosis. Following 1:1 propensity score matching, both the GLP-1 RA user and non-user… More > Graphic Abstract

Se Ha Jang^1,2,#, Hyung Seok Kim^3,#, Jung Woo Eun^1,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.072240 - 30 December 2025

Abstract Hepatocellular carcinoma (HCC) remains one of the most prevalent and lethal malignancies worldwide. Long non-coding RNAs (lncRNAs) have emerged as crucial regulators of gene expression and cancer progression, yet the functional diversity of RP11-derived lncRNAs—originally mapped to bacterial artificial chromosome (BAC) clones from the Roswell Park Cancer Institute—has only recently begun to be appreciated. This mini-review aims to systematically synthesize current findings on RP11-derived lncRNAs in HCC, outlining their genomic origins, molecular mechanisms, and biological significance. We highlight their roles in metabolic reprogramming, microRNA network modulation, and tumor progression, as well as their diagnostic and More >

Dongchi Cai^1,2,#, Jialin Ji^3,#, Chunhui Yang^1,*, Hong Cai^1,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.071152 - 30 December 2025

Abstract Metabolic reprogramming involving branched-chain amino acids (BCAAs)—leucine, isoleucine, and valine—is increasingly recognized as pivotal in cancer progression, metastasis, and immune modulation. This review comprehensively explores how cancer cells rewire BCAA metabolism to enhance proliferation, survival, and therapy resistance. Tumors manipulate BCAA uptake and catabolism via high expression of transporters like L-type amino acid transporter 1 (LAT1) and enzymes including branched chain amino acid transaminase 1(BCAT1), branched chain amino acid transaminase 2 (BCAT2), branched-chain alpha-keto acid dehydrogenase (BCKDH), and branched chain alpha-keto acid dehydrogenase kinase (BCKDK). These alterations sustain energy production, biosynthesis, redox homeostasis, and oncogenic… More >

Wen-Shou Tan^1,#, Hsuan Kuo^2,#, Chang-Ge Jiang¹, Mei-Han Lu¹, Yi-He Lu¹, Yung-Li Wang¹, Ching-Shuen Wang¹, Thi Thuy Tien Vo³, I-Ta Lee^1,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070871 - 30 December 2025

Abstract This narrative review examines recent advances in salivary biomarkers for oral squamous cell carcinoma (OSCC), a major subtype of oral cancer with persistently low five-year survival rates due to delayed diagnosis. Saliva has emerged as a noninvasive diagnostic medium capable of reflecting both local tumor activity and systemic physiological changes. Various salivary biomarkers, including microRNAs, cytokines, proteins, metabolites, and exosomes, have been linked to oncogenic signaling pathways involved in tumor progression, immune modulation, and therapeutic resistance. Advances in quantitative polymerase chain reaction, mass spectrometry, and next-generation sequencing have enabled comprehensive biomarker profiling, while point-of-care detection More >

Jing Shan¹, Catherine King^2,3, Harunor Rashid^3,4, Veysel Kayser^1,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070851 - 30 December 2025

Abstract Objectives: B-cell maturation antigen (BCMA)-targeted antibody–drug conjugates (ADCs) have emerged as promising therapies for relapsed/refractory multiple myeloma (RRMM), but the overall efficacy and safety profile is unclear. This study aimed to synthesize the available evidence on the safety and efficacy of BCMA-ADCs in development for RRMM. Methods: A systematic search was conducted using six bibliographic databases and ClinicalTrials.gov up to November 2024. Studies were eligible if they were human clinical trials or animal studies evaluating BCMA-ADCs and reported efficacy and safety outcomes. Data extraction and quality assessments were conducted using validated tools, including ROBINS-I… More >

Sarra B. Shakartalla^1,2,3, Iman M. Talaat^1,2,4,*, Nival Ali¹, Shahenaz S. Salih^1,5, Zainab M. Al Shareef^1,2, Noura Alkhayyal⁶, Riyad Bendardaf^2,7,*, Sameh S. M. Soliman^1,8,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070808 - 30 December 2025

Abstract Objectives: Breast cancer (BC) is the leading cause of cancer-related mortality in women, largely due to metastasis. This study aims to explore the role of purine nucleoside phosphorylase (PNP), a key enzyme in purine metabolism, in the aggressiveness and metastatic behavior of BC. Methods: A comprehensive analysis was performed using in silico transcriptomic data (n = 2509 patients), immunohistochemical profiling of BC tissues (n = 103), and validation through western blotting in multiple BC cell lines. Gene expression and survival analyses were conducted using Tumor Immune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis 2 (GEPIA2), and… More >